Data from 4727 invasive isolates of Streptococcus pneumoniae submitted to the Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus Reference Laboratory between 1999 and 2007 were analysed to establish susceptibility profiles to penicillin, erythromycin and cefotaxime. Pneumococcal resistance to penicillin over the study period remained low, with only 0.2 % (n57/4727) of isolates falling into this category (MIC ¢2 mg l "1 ). These isolates have been sporadic, and have mainly represented serogroup 14 (ST9) and 9 (ST156). In comparison, the 'intermediate sensitivity' group (MIC 0.12-1 mg l "1 ) ranged between 2 and 6 % per year, the majority from serogroup 9 (ST156). Over the study period, we found that 12 % (n5585/4727) of isolates were erythromycin-resistant (MIC .0.5 mg l "1 ), with the majority (n5467; 80 %) of these isolates identified as serogroup 14 (ST9). Cephalosporin resistance (cefotaxime MIC .1 mg l "1 ) was found in only 0.06 % (n52/3135) of isolates. Internationally recognized clones (Pneumococcal Molecular Epidemiology Network) accounted for 35 % (n528/81) of the penicillin non-susceptible isolates and 75 % (n5248/330) of the macrolide-resistant isolates, with ST9 and ST306 predominating. Between 1999 and 2007 we found that 11.6 % (n518/155) of the penicillin non-susceptible isolates and 4.8 % (n528/585) of the macrolide-resistant isolates were from serogroups not covered by the 7-valent conjugate pneumococcal vaccine in use in the UK since 2006. Susceptibility to first-line antimicrobial agents for invasive pneumococcal disease in Scotland remained high over the period 1999-2007. 
INTRODUCTION
Penicillin resistance in Streptococcus pneumoniae was first reported in 1967 (Hansman & Bullen, 1967) . Antibiotic resistance is now widespread, and this may contribute to increased morbidity, mortality and cost, although the clinical impact of in vitro resistance varies by disease process. Pneumococcal meningitis caused by penicillinresistant strains responds poorly to penicillin therapy, whereas pneumonia caused by resistant strains may still be successfully treated with penicillin (Song et al., 2004) . This is reflected in the differing MIC breakpoints for susceptibility to penicillin for these pathologies (BSAC, 2008) .
Rates of reported antimicrobial resistance in the pneumococcus vary greatly, both between and within countries.
The SENTRY surveillance program demonstrated that less than 20 % of bloodstream infections caused by S. pneumoniae were penicillin-resistant (Biedenbach et al., 2004) . In comparison, the Alexander Project showed that 57 % of non-invasive isolates from France were penicillin non-susceptible and 50 % were macrolide-resistant (Jacobs et al., 2003) . This variability in resistance may be due to a combination of differing patterns of antibiotic use within the community, coverage with the 7-valent pneumococcal conjugate vaccine (PCV-7) (introduced into the childhood vaccination schedule in the UK in September 2006), and spread of internationally recognized antibiotic-resistant clones (McGee et al., 2001) . Previous Scottish data from 1988-1999 demonstrated that the prevalence of penicillin intermediate sensitivity among invasive isolates was 2 % and penicillin resistance was 0.04 % (Kyaw et al., 2000) .
The aims of this study were to identify the susceptibility profiles to three first-line antibiotics (penicillin, erythromycin, cefotaxime) of S. pneumoniae isolates causing invasive pneumococcal disease in Scotland. We establish the contribution that differing serogroups and sequence types (STs) make to the burden of antibiotic resistance and the extent to which these are covered by PCV-7 and PCV-13. Finally, we explore the extent to which internationally recognized pneumococcal clones are seen within Scotland. Typing of isolates. All isolates were serogrouped by co-agglutination, as described by Smart (1986) . Full serotyping (a more discriminatory typing method) was carried out on all isolates submitted between 2003 and 2007. Multilocus sequence typing (MLST) (Enright & Spratt, 1998) was performed using a semiautomated technique on all samples from 2003-2007 (n53073) (Jefferies et al., 2003) . The Pneumococcal Molecular Epidemiology Network (PMEN) strains are international pneumococcal clones which may be associated with increased antibiotic resistance. They were identified by a combination of serotype and MLST (www.sph. emory.edu/PMEN/index.html).
METHODS

RESULTS AND DISCUSSION
Penicillin non-susceptibility There were 4727 invasive isolates included for analysis, submitted between 1999 and 2007. Pneumococcal resistance to penicillin over the study period remained rare, with only 0.15 % (n57, 95 % CI 0.07-0.31 %) of isolates falling into this category (MIC ¢2 mg l 21 ) ( Table 1) . These isolates were sporadic, and were mainly represented by serogroup 14. In comparison, 148 isolates (3.1 %, 95 % CI 2.7 -3.7 %) were identified in the 'intermediate sensitivity' group (MIC 0.12-1 mg l 21 ), with an incidence ranging from 6.2 % (95 % CI 3.8-9.9 %) in 1999 to 2. Penicillin non-susceptible organisms accounted for 3 % (n5155) of those analysed during the current 9 year study, which is an increase from the 2 % previously reported in 
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Scotland (Kyaw et al., 2000) . The 155 penicillin nonsusceptible isolates were isolated mainly from patients over 65 years of age (n587, 56 %), with 22 samples originating from children under 16 years (14 %), of which 13 were from children under 2 years of age (8 %). Non-susceptibility to penicillin varied with age (P50.01), with nonsusceptibility of 4.1 % (95 % CI 3.3-5.0 %) among those aged 65 and over, 2.4 % (95 % CI 1.8 -3.2 %) among those aged 16-64, and 3.1 % (95 % CI 2.1-4.7 %) in children.
A small proportion (n5171; 4 %) of the total number of invasive isolates were from CSF, and of these, six (4 %) were of intermediate penicillin sensitivity. In total, 4531 (96 %) of the isolates over the study period were from blood, and 143 of these blood culture isolates (3 %) were non-susceptible to penicillin. There is no evidence that the source of the sample influences sensitivity to penicillin (P50.07).
The clinical significance of intermediate sensitivity to penicillin in non-meningeal pneumococcal infections is doubtful (Choi & Lee, 1998) , as the levels of drug in the affected tissues are usually higher than the MIC of the organism (Hieber & Nelson, 1977) . Consequently, adequate dosing may still result in good clinical response (Musher et al., 2001 Ten serogroups were identified among the 155 nonsusceptible isolates submitted throughout the duration of the study (1, 3, 6, 8, 9, 14, 19, 23, 35 and 38) (Table 2) . Of these, five serogroups/types (1, 3, 8, 35 and 38) are not covered by the PCV-7 introduced into the UK in 2006. These accounted for 11.6 % of the non-susceptible isolates [n518 (95 % CI 7.5-17.6 %)]. Forty-seven per cent of all invasive pneumococcal disease cases had serogroups covered by the PCV-7 vaccine. However, seven of those non-susceptible isolates not covered by the vaccine were isolated in 2007 (after the introduction of the PCV).
In the years where full serotype information was available (2003) (2004) (2005) (2006) (2007) , 11 serotypes were identified from the penicillin non-susceptible isolates (1, 3, 4, 6A, 6B, 9V, 14, 19A, 19F, 23F and 35B) (Table 3 ). The PCV-7 covers 64 of the 77 (typable) non-susceptible strains isolated over this 5 year period (83 %). This figure rises to 92.2 % with the PCV-13. The principal serotype not covered by the vaccine is 35B (n56). ST156 accounted for two of the penicillin-resistant clones, and ST246 accounted for one. MLST data were unavailable for the remaining two resistant isolates.
Cephalosporin resistance
The MICs of cefotaxime were only available for the 3135 isolates submitted between 2003 and 2007. Two resistant isolates were identified, and both of these were recovered from blood. These were serotype 14 and 22F, and were isolated from patients aged 1 and 85 years, respectively. Cephalosporin resistance in pneumococci is rare in Scotland (0.06 % of isolates). This finding supports current guidelines, which recommend the use of a cephalosporin as first-line therapy in the treatment of bacterial meningitis, with the addition of vancomycin in the case of suspected cephalosporin or penicillin resistance (Chaudhuri et al., 2008) .
Macrolide resistance
Of the 4727 isolates analysed, 585 were erythromycinresistant [12.3 % (95 % CI 11.5 -13.3 %)] ( Table 1) There were 22 different serogroups isolated, and of these serotype 14 made up the majority [467 isolates, 80 % (95 % CI 76.4-82.9 %)]. The overlap between macrolide and penicillin non-susceptibility was only 0.9 % (n544). The practice of adding a macrolide to a b-lactam for the treatment of severe community-acquired pneumonia (Lim et al., 2009 ) is supported as a means of ensuring that the 
PMEN clones
The PMEN strains are international pneumococcal clones identified by a combination of serotype and MLST. This gives more accurate data on clonal spread than serotype alone, as capsular serogroup switching has been described (Jefferies et al., 2004 (Brueggemann & Spratt, 2003) .
Pneumococcal conjugate vaccine coverage
Over the study period, 12 % (n518/155) of the penicillin non-susceptible and 9 % of the macrolide-resistant isolates were from serogroups not covered by the PCV-7 (Table 2 ). The conjugate vaccine was introduced in 2006 in the UK, and so it is not possible from the current data presented here to determine whether there has been serotype replacement among invasive strains by the serotypes not covered by the vaccine, as has been reported in the case of serotype 19A in the USA (Pelton et al., 2007) and Europe (Ardanuy et al., 2009) . Only three isolates with serotype 19A were identified in the current study. In spring 2010, the new PCV-13 was introduced in Scotland (Department of Health, 2010). It additionally covers serotypes 1, 3, 5, 6A, 7F and 19A. Only 9 % (n514/155) of penicillin non-susceptible isolates from the current study would not be covered by the PCV-13.
In conclusion, we report relatively low levels of antimicrobial resistance in invasive pneumococci from Scotland to the common first-line antibiotics used in the treatment of pneumococcal infections. The most common serotype demonstrating reduced susceptibility to penicillin was represented by the serogroup 9 and ST156 clones. The most common serotype demonstrating reduced susceptibility to erythromycin was 14 (ST9) (the England 14 ST9 strain). Whilst there are a large number of PMEN clones represented in our collection of invasive pneumococcal isolates, many of those identified are not associated with resistance to first-line antibiotic agents.
Antibiotic resistance was identified most commonly in serogroups covered by the PCV-7, and non-susceptibility was rare among non-vaccine serogroups. The principal serotype associated with penicillin non-susceptibility not covered by the PCV-7 or the new PCV-13 was 35B. Continued surveillance for emergence of vaccine escape serotypes and their antimicrobial susceptibility is advised and studies investigating the continued low prevalence of antimicrobial-resistant pneumococci in Scotland, whilst the prevalence remains much higher elsewhere in Europe with comparable rates of community antibiotic use, may help shed light on selection pressures for emergence of resistant isolates.
